However, a significant association between the BDNF polymorphism and improvements of several clinical measures was observed in a double-blind randomized placebo-controlled clinical trial of sertraline in FXS aimed to determine the efficacy of treatment in young children with FXS [157]. The gene discussed is BDNF; the disease is fragile X syndrome.